We are live on
!
Find out more
Immunovant
IMVT
IMVT
215 hedge funds and large institutions have $2.75B invested in Immunovant in 2026 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 93 increasing their positions, 40 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
619% more call options, than puts
Call options by funds: $61.3M | Put options by funds: $8.52M
133% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 40
92% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 24
10% more funds holding
Funds holding: 196 → 215 (+19)
1% less capital invested
Capital invested by funds: $2.76B → $2.75B (-$14.3M)
7.63% less ownership
Funds ownership: 61.96% → 54.34% (-7.6%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Holders
215
Holders Change
+19
Holders Change %
+9.69%
% of All Funds
2.65%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.09%
New
46
Increased
93
Reduced
40
Closed
24
Calls
$61.3M
Puts
$8.52M
Net Calls
+$52.8M
Net Calls Change
+$26.3M
Top Buyers
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$56.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$50.8M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$37.5M |
| 4 |
Morgan Stanley
New York
|
-$25.1M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$22.8M |
